In previous studies, TianDiJingWan treatment significantly reduced p-tau aggregation and improved learning and memory in an AD rat model [32], and the Aβ-N-terminus monoclonal antibody (mAb) A8 decreased levels of both Aβ and p-tau in the brains of APP/PS1 mice and alleviated cognitive dysfunction [33]. This evidence concerns the gene MAPT and Alzheimer disease.